Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Ann Neurol. 2019 Apr 26;85(6):921–926. doi: 10.1002/ana.25477

Figure 3. The SLC1A2 modulating agent ceftriaxone does not significantly alter daily spasm count in a 20-month-old heterozygous for Leu85Pro SLC1A2.

Figure 3.

(Left) Daily spasm counts before, during and after a 14 day trial of IV ceftriaxone in a 20-month-old girl with a heterozygous Leu85Pro SLC1A2 variant causing SLC1A2-related epilepsy. EEG verified daily epileptic spasms are indicated in green. (Right) Box-and-whisker plots showing the median, quartile and minimum/maximum daily spasm counts across the 13 days without ceftriaxone treatment and the 15 days with ceftriaxone treatment. P-value calculated using the two-tailed Welch’s t-test.